YM155 + Docetaxel as 1st-Line Treatment for Metastatic Breast Cancer

• Research type

  Research Study

• Full title

  A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer

• IRAS ID

  33126

• Contact name

  Tamas Hickish

• Contact email

  Tamas.Hickish@rbch.nhs.uk

• Sponsor organisation

  Astellas Pharma Global Development, Inc (APGD-US)

• Eudract number

  2009-012439-14

• ISRCTN Number

  NO

• Clinicaltrials.gov Identifier

  NCT01038804

• Research summary

  exceeds word count do not publish

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  10/H0504/15

• Date of REC Opinion

  16 Apr 2010

• REC opinion

  Further Information Favourable Opinion